HUGH M MORGAN AC - Chairman

Hugh Morgan is Principal of First Charnock. He is a member of the Lafarge International Advisory Board; an Emeritus Trustee of The Asia Society New York; Chairman Emeritus of the Asia Society AustralAsia Centre; President of the National Gallery of Victoria Foundation and Chairman of the Order of Australia Association Foundation. He was a Director of the Board of the Reserve Bank of Australia for 14 years. From 2003–2005 he was President of the Business Council of Australia. He is also immediate Past President of the Australia Japan Business Co-operation Committee and a Past Co-Chair of the Commonwealth Business Council and continuing Director. He is a graduate in Law and Commerce from the University of Melbourne and was Chief Executive Officer of WMC Limited from 1986 to 2003. He was a Director of Alcoa of Australia from 1977 to 1998 and a Director of Alcoa Inc from 1998 to 2001.

PROFESSOR LARISA RUDENKO- Non-Executive Director

Professor Rudenko is Head of the Virology Department in the Institute of Experimental Medicine, St. Petersburg, Russia. Professor Rudenko worked with Academician Smorodintsev and has been responsible for the development and clinical trials of the live attenuated influenza vaccines in Russia. She is recognised as one of the world’s leading experts in live attenuated influenza vaccines and as such has worked closely over the past 20 years with scientists at the Centers for Disease Control and Prevention, Atlanta, USA in developing effective influenza prophylaxis programs for use in children and in the elderly. She has published in excess of 225 scientific papers and 42 patents. Under her supervision, 11 PhD and 2 DSc thesis have been prepared. In 1999 her contribution to medical science was recognised with the award of the title of Honoured Scientist of the Russian Federation. Professor Rudenko is currently leading the WHO and PATH program, developing a new pandemic LAIV for developing countries.

DON BROOKS - Non-Executive Director

Don Brooks, a graduate of Columbia University School of Law, is a US-based lawyer, who for many years was Senior Counsel-Licensing at Merck & Co., Inc. and was formerly its Counsel for U.S. pharmaceutical operations and Counsel for its research operations. Don retired from Merck in 1993 and since that time has served as Counsel to a U.S. law firm representing clients in the biotechnology industry, as well as serving as an advisor to firms in the biotechnology and the pharmaceutical industry in general. He has been general counsel of a Maryland-based biotech company, EntreMed Inc. and currently serves on the Board of that company.

PROFESSOR ARTHUR LI - Non-Executive Director

Professor Arthur Li was awarded the degree of Doctor of Medicine by University of Cambridge, UK.  He is a well-credentialed and respected educator and surgeon who is currently Deputy Chairman of The Bank of East Asia and is Emeritus Professor of Surgery of The Chinese University of Hong Kong.  He is also a director of AFFIN Holdings Berhad.

Among his many previous appointments and associations, he has been a Council Fellow of the University of Melbourne, Dean of the Faculty of Medicine and Vice-Chancellor of The Chinese University of Hong Kong.  Professor Li was the Secretary for Education and Manpower and a Member of the Executive Council of the Government of HKSAR.  He was also a member of the board of GlaxoWellcome plc.  He is a member of the National Committee of the Chinese People’s Political Consultative Conference.

JULIE PHILLIPS – Executive Director & Chief Executive Officer

Ms Phillips was appointed to the position of Chief Executive Office on July 1, 2009 and was appointed a director on May 7, 2010.  She has a strong background in the biotech and pharmaceutical industry, having worked as the CEO and director of start-up Australian biotechnology companies operating in the life sciences sector. Her technical background in clinical trials, regulatory affairs and pharmaco-economic assessment/pricing of therapeutics was gained in multinational pharmaceutical companies with responsibility for market entry of new products in Australia and New Zealand. Ms Phillips is also on the Board of the CRC for Asthma and Airways Ltd.

RICHARD WADLEY - Company Secretary/Chief Financial Officer

Richard Wadley, FCCA, was appointed to the position of Company Secretary and Chief Financial Officer in 2002.Mr Wadley has previously held positions of Company Secretary and Chief Financial Officer at a number of companies including Biota and AC Goode & Co Stockbrokers. Richard has considerable experience within the biotech sector and provides financial, secretarial and management assistance to a number of early stage life science companies.

CATHY CROPP - Projects Manager

Ms Cropp was appointed Projects Manager in 2010 and is responsible primarily for managing the LAIV vaccine vector and BDM-I anti-microbial projects. Cathy is a microbiologist with over 20 years experience in international quality/compliance, manufacturing and drug, biologicals and vaccine development management in both the international and domestic pharmaceutical and biotech sectors. Her core skills revolve around Good Laboratory, Manufacturing and Clinical Practice compliance on an international level. She has considerable knowledge in regulatory affairs and clinical development strategies and the development and implementation of manufacturing processes for investigational new therapeutic agents appropriate for clinical use.